Neurocrine Biosciences Receives Strong-Buy Upgrade from StockNews.com

On February 11th, 2025, Neurocrine Biosciences, listed on NASDAQ as NBIX, received an upgrade from StockNews.com, moving its rating from a buy to a strong-buy. This change reflects growing confidence among analysts regarding the company's prospects.

A variety of analysts have expressed their views on Neurocrine Biosciences recently. For instance, BMO Capital Markets lowered their price target from $128 to $114 while labeling the stock as a "market perform" in a report issued on October 17th. UBS Group increased their price target from $162 to $176, assigning a "buy" rating in their analysis released on January 30th.

Additionally, Wedbush decreased their price objective from $157 to $147, maintaining an "outperform" rating. Bank of America revised its price target from $184 to $179, also keeping a "buy" rating. Morgan Stanley established a new price target of $185, up from $170, while giving the stock an "overweight" rating in a report dated February 4th.

Overall, the consensus among analysts shows that four have given the stock a hold rating, while seventeen have rated it a buy, and two have assigned a strong buy rating. Research from MarketBeat.com indicates that Neurocrine has an average rating of "Moderate Buy" and an average target price set at $168.35.

Current Market Performance

On the trading day of the report, Neurocrine Biosciences opened at $118.81, reflecting a slight decline of 3.1%. The company has a market capitalization of $12.03 billion, a P/E ratio of 36.11, and a beta value of 0.33. Over the past year, the stock has fluctuated between a low of $110.95 and a high of $157.98, with current moving averages of $138.81 for 50 days and $131.42 for 200 days.

Neurocrine recently announced its quarterly earnings on February 6th, reporting earnings of $1.00 per share. This figure fell short of analyst expectations, which were set at $1.62. The company achieved a return on equity of 13.45% with a net margin of 14.49%. Looking ahead, analysts predict that Neurocrine is on track to post an EPS of 6.53 for the current fiscal year.

Insider Activity

In recent insider transactions, Ingrid Delaet, an insider of the company, sold 623 shares on February 3rd for an average price of $149.29, totaling approximately $93,007.67. Post-sale, she owns around 3,442 shares valued at about $513,856.18, which represents a 15.33% decrease in her shareholding. This transaction was publicly disclosed to the SEC. Additionally, CFO Matt Abernethy sold 1,283 shares on January 31st at an average price of $152.87, amounting to about $196,132.21. After this transaction, he holds 32,681 shares currently worth around $4,995,944.47, reflecting a 3.78% decrease in his ownership. In total, insiders sold around 222,693 shares worth approximately $32.72 million in the last quarter, with insiders collectively owning 4.30% of the company’s shares.

Institutional Investments

Neurocrine Biosciences has also seen shifts in institutional investor stakes. For instance, Golden State Wealth Management LLC acquired a new stake in the firm valued at about $25,000. Meanwhile, Brooklyn Investment Group boosted its position by 99.1% in the last quarter, now owning a total of 231 shares worth $32,000 after adding 115 shares. Other investors, such as Blue Trust Inc. and Lindbrook Capital LLC, have also increased their holdings in the company. Currently, a significant 92.59% of the stock is owned by institutional investors.

Company Overview

Neurocrine Biosciences, Inc. is focused on discovering, developing, and marketing pharmaceuticals that address neurological, neuroendocrine, and neuropsychiatric disorders. Their notable products include INGREZZA for treating tardive dyskinesia, ALKINDI for adrenal insufficiency, Efmody for classic congenital adrenal hyperplasia, and Orilissa for endometriosis. The company continues to explore new solutions to improve the lives of patients globally.

Neurocrine, Upgrade, Analysts